In silico Prediction of Anti–SARS-CoV-2 Effect of Dermaseptin Peptides from Amphibian Origin Prediction of anti–SARS-CoV-2 effect of the dermaseptin peptides
Trends in Peptide and Protein Sciences,
Vol. 5 (2020),
1 Dey 2020
,
Page 1-9 (e6)
https://doi.org/10.22037/tpps.v5i.32560
Abstract
The novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now been declared as a global pandemic by the World Health Organization (WHO). Several drug molecules have been proposed that can be used against the virus. As an alternative to effective drug molecules, the antiviral peptides have the potential for effective application to control the infectious disease. In this work, the anti- SARS-CoV-2 effect of dermaseptin peptide molecules produced by the skin of the frog was evaluated by using the computational method. Three numbers of antiviral dermaseptin peptides were obtained by searching the antimicrobial peptide database (APD). First, the structure prediction of peptides was done by Pep Fold 2.0 server followed by structure validation by PROCHECK program. Then, the protein-peptide docking simulations were performed using the COVID-19 docking server. The peptides' binding affinity with the SARS-CoV-2 spike protein macromolecule was evaluated along with eight negative control peptides and human angiotensin converting enzymes 2 (ACE2). The protein-peptide docking and interaction analysis resulted in finding that dermaseptin-S9 peptide molecule was the most efficient molecule among the selected peptides with a binding energy of -331.54 KJ/mole. Hence, as a follow-up study, the dermaseptin-S9 peptide molecule can be further designed to enhance its specificity and binding affinity for its better use against the SARSCoV-2 disease.
HIGHLIGHTS
- Three numbers of antiviral dermaseptin peptides from APD database were in silico evaluated against SARS-CoV-2 spike protein.
- The antiviral dermaseptin -S9 peptide showed the highest binding affinity towards the SARS-CoV-2 spike protein macromolecule.
- The hydrophobic property of the distributed amino acids of the derrmaseptin-9 molecule might be related to the binding affinity.
- Antimicrobial peptide
- Binding energy
- Dermaseptin
- Docking
- SARS-CoV-2
- Structure prediction
How to Cite
References
Amiche, M., Ladram, A. and P. Nicolas, (2008). "A consistent nomenclature of antimicrobial peptides isolated from frogs of the subfamily Phyllomedusinae." Peptides, 29(11): 2074-2082.
Aouni, M., Khelifa R. and K. Hani, (2002). "In vitro antiviral activity of dermaseptins against Herpes simplex virus type." Journal of Medical Virology, 66: 229-234.
Barh, D., Tiwari, S., Andrade, B. S., Giovanetti, M., Costa, E. A., Kumavath, R., Ghosh, P., Góes-Neto, A., Alcantara, L. C. J. and V. Azevedo, (2020). "Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain." F1000 Research, 9(576): 576.
Bergaoui, I., Zairi, A., Tangy, F., Aouni, M., Selmi, B. and K. Hani, (2013). "In vitro antiviral activity of dermaseptin S4 and derivatives from amphibian skin against herpes simplex virus type 2." Journal of Medical Virology, 85(2): 272-281.
Castel, G., Chtéoui, M., Heyd, B. and N. Tordo, (2011). "Phage display of combinatorial peptide libraries: application to antiviral research." Molecules, 16(5): 3499-3518.
Chen, Y., Guarnieri, M. T., Vasil, A. I., Vasil, M. L., Mant, C. T. and R. S. Hodges, (2007). "Role of peptide hydrophobicity in the mechanism of action of α-helical antimicrobial peptides." Antimicrobial Agents Chemotherapy, 51(4): 1398-1406.
Chen, Y., Guo, Y., Pan, Y. and Z. J. Zhao, (2020). "Structure analysis of the receptor binding of 2019-nCoV." Biochemical Biophysical Research Communications, 525(1): 135-140.
Da Mata, É. C. G., Mourão, C. B. F., Rangel, M. and E. F. Schwartz, (2017). "Antiviral activity of animal venom peptides and related compounds." Journal of Venomous Animals Toxins including Tropical Diseases, 23(1): 3.
Dathe, M. and T. Wieprecht, (1999). "Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells." Biochimica et Biophysica Acta –Biomembranes, 1462(1-2): 71-87.
De Lucca, A., Bland, J., Jacks, T., Grimm, C. and T. Walsh, (1998). "Fungicidal and binding properties of the natural peptides cecropin B and dermaseptin." Medical Mycology, 36(5): 291-298.
De Lucca, A. J. and T. J. Walsh, (1999). "Antifungal peptides: novel therapeutic compounds against emerging pathogens." Antimicrobial Agents Chemotherapy, 43(1): 1-11.
de Souza Cardoso, J. L. M., dos Santos Soares, M. J., Leite, J. R. S. A., Malaquias, L. C. C. and L. F. L. Coelho, (2013). "Antiviral activity of dermaseptin 01 against Dengue virus type 2, Herpes simplex virus type 1 and Vaccinia virus." Scientia Medica, 23(1): 3.
Elnagdy, S. and M. AlKhazindar, (2020). "The potential of antimicrobial peptides as an antiviral therapy against COVID-19." ACS Pharmacology Translational Science, 3(4): 780-782.
Epand, R. M. and H. J. Vogel, (1999). "Diversity of antimicrobial peptides and their mechanisms of action." Biochimica et Biophysica Acta –Biomembranes, 1462(1-2): 11-28.
Fakih, T. M. (2020). "Dermaseptin-Based Antiviral Peptides to Prevent COVID-19 through In Silico Molecular Docking Studies against SARS-CoV-2 Spike Protein." Pharmaceutical Sciences, 7(4): 8.
Feder, R., Dagan, A. and A. Mor, (2000). "Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity." Journal of Biological Chemistry, 275(6): 4230-4238.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H. and A. Nitsche, (2020). "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor." Cell, 181(2): 271-280.
Holthausen, D. J., Lee, S. H., Kumar, V. T., Bouvier, N. M., Krammer, F., Ellebedy, A. H., Wrammert, J., Lowen, A. C., George, S. and M. R. Pillai, (2017). "An amphibian host defense peptide is virucidal for human H1 hemagglutinin-bearing influenza viruses." Immunity, 46(4): 587-595.
Jaiswal, G. and V. Kumar, (2020). "In-silico design of a potential inhibitor of SARS-CoV-2 S protein." Plos One, 15(10): e0240004.
Kam, Y.-W., Okumura, Y., Kido, H., Ng, L. F., Bruzzone, R. and R. Altmeyer, (2009). "Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro." Plos One, 4(11): e7870.
Kong, R., Wang, F., Zhang, J., Wang, F. and S. Chang, (2019). "CoDockPP: A Multistage Approach for Global and Site-Specific Protein–Protein Docking." Journal of Chemical Information Modeling, 59(8): 3556-3564.
Kong, R., Yang, G., Xue, R., Liu, M., Wang, F., Hu, J., Guo, X. and S. Chang, (2020). "COVID-19 Docking Server: A meta server for docking small molecules, peptides and antibodies against potential targets of COVID-19." Bioinformatics, In Press.
Krugliak, M., Feder, R., Zolotarev, V. Y., Gaidukov, L., Dagan, A., Ginsburg, H. and A. Mor, (2000). "Antimalarial activities of dermaseptin S4 derivatives." Antimicrobial Agents Chemotherapy, 44(9): 2442-2451.
Lam, S. D., Bordin, N., Waman, V. P., Scholes, H. M., Ashford, P., Sen, N., Van Dorp, L., Rauer, C., Dawson, N. L. and C. S. Pang, (2020). "SARS-CoV-2 spike protein predicted to form stable complexes with host receptor protein orthologues from mammals." Scientific Reports, 10: 16471.
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q. and L. Zhang (2020). "Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor." Nature Microbiology, 581(7807): 215-220.
Letko, M., Marzi, A. and V. Munster, (2020). "Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses." Nature Microbiology, 5(4): 562-569.
Mahendran, A. S. K., Lim, Y. S., Fang, C.-M., Loh, H.-S. and C. F. Le, (2020). "The Potential of Antiviral Peptides as COVID-19 Therapeutics." Frontiers in Pharmacology, 11: 1475.
Matejuk, A., Leng, Q., Begum, M., Woodle, M., Scaria, P., Chou, S. and A. Mixson, (2010). "Peptide-based antifungal therapies against emerging infections." Drugs of the Future, 35(3): 197.
Maupetit, J., Derreumaux, P. and P. Tuffery, (2009). "PEP-FOLD: an online resource for de novo peptide structure prediction." Nucleic Acids Research, 37(suppl_2): W498-W503.
Mehra, M. R., Desai, S. S., Kuy, S., Henry, T. D. and A. N. Patel, (2020). "Cardiovascular disease, drug therapy, and mortality in COVID-19." New England Journal of Medicine, 382(25): e102.
Mor, A. and P. Nicolas, (1994). "Isolation and structure of novel defensive peptides from frog skin." European Journal of Biochemistry, 219(1‐2): 145-154.
Mor, A. and P. Nicolas, (1994). "The NH2-terminal alpha-helical domain 1-18 of dermaseptin is responsible for antimicrobial activity." Journal of Biological Chemistry, 269(3): 1934-1939.
Muhseen, Z. T., Hameed, A. R., Al-Hasani, H. M., ul Qamar, M. T. and G. Li, (2020). "Promising terpenes as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor: Integrated computational approach." Journal of Molecular Liquids, 320: 114493.
Mujtaba, M. G., Patel, C. B., Patel, R. A., Flowers, L. O., Burkhart, M. A., Waiboci, L. W., Martin, J., Haider, M. I., Ahmed, C. M. and H. M. Johnson, (2006). "The gamma Interferon (IFN-γ) mimetic peptide IFN-γ (95-133) prevents Encephalomyocarditis Virus infection both in tissue culture and in mice." Clinical Vaccine Immunology, 13(8): 944-952.
Mustafa, S., Balkhy, H. and M. Gabere, (2019). "Peptide-protein interaction studies of antimicrobial peptides targeting middle east respiratory syndrome coronavirus spike protein: an in silico approach." Advances in Bioinformatics, 2019.
Neiva, M., Vargas, D., Conceição, K., Rádis-Baptista, G., Assakura, M., Jared, C. and M. A. F. Hayashi, (2013). "Gene expression analysis by ESTs sequencing of the Brazilian frog Phyllomedusa nordestina skin glands." Toxicon, 61: 139-150.
Nicolas, P. and C. El Amri, (2009). "The dermaseptin superfamily: a gene-based combinatorial library of antimicrobial peptides." Biochimica et Biophysica Acta –Biomembranes, 1788(8): 1537-1550.
Ou, X., Guan, H., Qin, B., Mu, Z., Wojdyla, J. A., Wang, M., Dominguez, S. R., Qian, Z. and S. Cui, (2017). "Crystal structure of the receptor binding domain of the spike glycoprotein of human betacoronavirus HKU1." Nature Communications, 8: 15216.
Rinaldi, A. C. (2002). "Antimicrobial peptides from amphibian skin: an expanding scenario: Commentary." Current Opinion in Chemical Biology, 6(6): 799-804.
Rivas, L., Luque-Ortega, J. R. and D. Andreu, (2009). "Amphibian antimicrobial peptides and Protozoa: lessons from parasites." Biochimica et Biophysica Acta –Biomembranes, 1788(8): 1570-1581.
Robson, B. (2020). "COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles’ heel conserved region to minimize probability of escape mutations and drug resistance." Computers in Biology Medicine, 121: 103749.
Rotem, S., Radzishevsky, I. and A. Mor, (2006). "Physicochemical properties that enhance discriminative antibacterial activity of short dermaseptin derivatives." Antimicrobial Agents Chemotherapy, 50(8): 2666-2672.
Satpathy, R. (2020). "In Silico based Whole Genome Phylogenetic Analysis of Novel Coronavirus (SARS-CoV-2)." International Journal on Emerging Technologies, 11(3): 1157-1163.
Shai, Y. (1999). "Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by α-helical antimicrobial and cell non-selective membrane-lytic peptides." Biochimica et Biophysica Acta –Biomembranes, 1462(1-2): 55-70.
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach A. and F. Li, (2020). "Structural basis of receptor recognition by SARS-CoV-2." Nature, 581(7807): 221-224.
Shen, Y., Maupetit, J., Derreumaux, P. and P. Tufféry, (2014). "Improved PEP-FOLD approach for peptide and miniprotein structure prediction." Journal of Chemical Theory Computation, 10(10): 4745-4758.
Sukhwal, A. and R. Sowdhamini, (2013). "Oligomerisation status and evolutionary conservation of interfaces of protein structural domain superfamilies." Molecular BioSystems, 9(7): 1652-1661.
Tossi, A., Sandri, L. and A. Giangaspero, (2000). "Amphipathic, α‐helical antimicrobial peptides." Peptide Science, 55(1): 4-30.
Velavan, T. P. and C. G. Meyer, (2020). "The COVID‐19 epidemic." Tropical Medicine International Health, 25(3): 278.
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T. and D. Veesler, (2020). "Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein." Cell, 181(2): 281-292.
Xia, S., Yan, L., Xu, W., Agrawal, A. S., Algaissi, A., Tseng, C.-T. K., Wang, Q., Du, L., Tan, W.and I. A. Wilson, (2019). "A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike." Science Advances, 5(4): eaav4580.
Zaïri, A., Ferrières, L., Latour-Lambert, P., Beloin, C., Tangy, F., Ghigo, J.-M. and K. Hani, (2014). "In vitro activities of dermaseptins K4S4 and K4K20S4 against Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa planktonic growth and biofilm formation." Antimicrobial Agents Chemotherapy, 58(4): 2221-2228.
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B. and C.-L. Huang (2020). "A pneumonia outbreak associated with a new coronavirus of probable bat origin." Nature, 579(7798): 270-273.
- Abstract Viewed: 351 times
- PDF Downloaded: 163 times